Spinal cord stimulation for the treatment of painful diabetic neuropathy and risk of major adverse cardiovascular events, mortality, amputation, infection and suicide: a retrospective cohort study.

ABSTRACT:

Background

Spinal cord stimulation (SCS) has recently been approved by the US Food and Drug Administration (FDA) for the treatment of refractory painful diabetic neuropathy (PDN), although the current evidence for efficacy is limited by small sample sizes and short follow-up. We aimed to assess the benefits of SCS, compared to combination pharmacotherapy (gabapentinoid plus duloxetine), in a large population of PDN patients using real-world evidence.

Methods

We performed a real-world cohort study of electronic medical records using the TriNetX network, a global federated database (9th September 2024). The treatment arm was patients with PDN (defined as diabetes plus neuropathic pain treatment) treated with SCS (refractory to pharmacotherapy), compared against a reference arm

SUBMITTER: Henney AE 

PROVIDER: S-EPMC12508579 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature